Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has…

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER! We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is…

Copenhagen, June 9 2016. At the 21st Congress of the European Hematology Association (EHA) in Copenhagen, in total thirteen hematology researchers will be awarded for their work. Research is the engine that drives improvements in patient care which is why EHA is keen in investing in Awards and Grants to stimulate and support hematology research.

The Hague, January 27, 2016 In the February 2016 issue of Haematologica, critical research of blood and blood-forming organs in Europe is given a boost. The European Hematology Association Roadmap for European Hematology Research: A Consensus Document summarizes the current status of basic, translational and clinical hematology research and identifies areas of unmet scientific and medical need in Europe. It provides guidance for European and national policy makers, funding agencies, charities, research institutes and researchers when they make decisions on initiating or funding research and developing research programs.

You may have heard of European Reference Networks (ERNs). But most likely you have not because they do not exist yet. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases and they are foreseen to be established by the end of this year. EHA wants to support the establishment of an ERN for Rare Hematological Diseases.

We need your input to improve Horizon 2020 and the next Research and Innovation Framework Programme of the European Union.

On October 6, 2015, the Innovative Medicines Initiative (IMI) launched its 6^th Call for proposals under IMI 2. This call includes, under the program “Big Data for Better Outcomes programme”, the topic:
Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies.

Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.

Vienna, June 12, 2015 – On behalf of the EUTOS network, Dr Hoffmann will present data of a web-based registry of newly diagnosed CML patients.

Vienna, June 12, 2015 – On behalf of the ELOQUENT-2 investigators, Dr Dimopoulos will present the positive results on Elotuzumab with Lenalidomide from a phase III study in patients with multiple myeloma.

Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.

Vienna, June 12, 2015 –Dr Marneth will discuss the findings of eight new genetic variants in GFI1B that have been discovered in patients with bleeding and platelet disorders and consequences for new therapeutic targets.

Vienna, June 12, 2015 –Dr Mesa will present new data from the phase 3 PERSIST-1 study on improving disease symptoms and quality of life for patients with myelofibrosis.

Vienna, June 12, 2015 – Dr Ehninger will present the results of a phase II randomized study on the safety and efficacy of Sorafenib.

At the Congress of the European Hematology Association (EHA) – attracting 10,000 hematologists from Europe and beyond - the president of EHA, Prof. Christine Chomienne, called upon the European Union to deliver funding for Research into Blood Disorders:

“The hematologists in Europe have done a great work. Now it’s the EU’s turn to deliver.”